Capricor Therapeutics Investors Face Securities Fraud Class Action Lawsuit Opportunity
In a recent development, Glancy Prongay Wolke & Rotter LLP, a prominent law firm specializing in shareholder rights, has announced the opening of a class action lawsuit for investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) who experienced financial losses. The lawsuit aims to address a series of misleading statements and omissions made by the company and its executives.
Between December 17, 2025 and July 26, 2026, Capricor allegedly communicated materially false information to its shareholders. They failed to disclose critical facts that could potentially have a significant impact on the perception of the company's business viability and the anticipated success of its key drug, Deramiocel, intended for treating Duchenne muscular dystrophy (DMD). Particularly, investors were not made aware of modifications to the statistical analysis plan for Deramiocel's clinical data and the lack of pre-approval from the FDA for these changes. Furthermore, there was a risk that the FDA might find the results insufficient to support its efficacy claims.
These misrepresentations leave investors in a tough spot, not only regarding their current investments but also about the future of the firm. Shareholders are encouraged to act swiftly to recover their losses through participation in the class action lawsuit. The deadline for those interested in becoming a lead plaintiff is September 28, 2026, highlighting the urgency for affected parties.
For investors who have suffered financial setbacks due to their investments in Capricor Therapeutics, the opportunity to step forward in the lawsuit marks a critical chance for restitution. The law firm is accepting inquiries and is poised to help potential plaintiffs navigate through the legalities involved in pursuing claims against the company. Interested parties are advised to contact Glancy Prongay Wolke & Rotter LLP through their provided email or telephone numbers to explore further options regarding their rights and interests.
Having established a solid reputation over decades in the legal field, Glancy Prongay Wolke & Rotter LLP is recognized for their commitment to representing shareholders and consumers in complex litigation scenarios. They have recently received accolades for their successes in securities litigation, establishing a narrative of being a reliable partner for investors seeking justice. The firm's record includes high-profile cases and significant recoveries for clients, which reinforces their proficiency in such complex matters.
If you’re an investor within the significant timeline and believe that you have been adversely affected, consider reaching out without delay. Participation in this class action could be critical in reclaiming your investments and holding companies accountable for misleading practices.
In conclusion, this ongoing situation around Capricor Therapeutics serves as a reminder for investors to stay vigilant and proactive about their investments, especially in the face of potential corporate misconduct. The path to recovery through this lawsuit could create an avenue for justice for those affected by the alleged fraud. Navigate carefully, and seek expert legal advice to ensure your rights are upheld in this critical matter.
Background of the Case
Between December 17, 2025 and July 26, 2026, Capricor allegedly communicated materially false information to its shareholders. They failed to disclose critical facts that could potentially have a significant impact on the perception of the company's business viability and the anticipated success of its key drug, Deramiocel, intended for treating Duchenne muscular dystrophy (DMD). Particularly, investors were not made aware of modifications to the statistical analysis plan for Deramiocel's clinical data and the lack of pre-approval from the FDA for these changes. Furthermore, there was a risk that the FDA might find the results insufficient to support its efficacy claims.
These misrepresentations leave investors in a tough spot, not only regarding their current investments but also about the future of the firm. Shareholders are encouraged to act swiftly to recover their losses through participation in the class action lawsuit. The deadline for those interested in becoming a lead plaintiff is September 28, 2026, highlighting the urgency for affected parties.
What Can Investors Do?
For investors who have suffered financial setbacks due to their investments in Capricor Therapeutics, the opportunity to step forward in the lawsuit marks a critical chance for restitution. The law firm is accepting inquiries and is poised to help potential plaintiffs navigate through the legalities involved in pursuing claims against the company. Interested parties are advised to contact Glancy Prongay Wolke & Rotter LLP through their provided email or telephone numbers to explore further options regarding their rights and interests.
Glancy Prongay Wolke & Rotter LLP's Role
Having established a solid reputation over decades in the legal field, Glancy Prongay Wolke & Rotter LLP is recognized for their commitment to representing shareholders and consumers in complex litigation scenarios. They have recently received accolades for their successes in securities litigation, establishing a narrative of being a reliable partner for investors seeking justice. The firm's record includes high-profile cases and significant recoveries for clients, which reinforces their proficiency in such complex matters.
If you’re an investor within the significant timeline and believe that you have been adversely affected, consider reaching out without delay. Participation in this class action could be critical in reclaiming your investments and holding companies accountable for misleading practices.
In conclusion, this ongoing situation around Capricor Therapeutics serves as a reminder for investors to stay vigilant and proactive about their investments, especially in the face of potential corporate misconduct. The path to recovery through this lawsuit could create an avenue for justice for those affected by the alleged fraud. Navigate carefully, and seek expert legal advice to ensure your rights are upheld in this critical matter.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.